Trillium Therapeutics Reports Second Quarter 2019 Financial Results
August 13, 2019 07:00 ET
|
Trillium Therapeutics Inc.
TORONTO, Aug. 13, 2019 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today...
Trillium Therapeutics Provides Corporate Update
July 24, 2019 07:00 ET
|
Trillium Therapeutics Inc.
FDA meeting scheduled to discuss the pivotal path for intratumoral TTI-621 in CTCLIntravenous TTI-621 protocol amended to enable dosing beyond 0.5 mg/kg and first patient cohort enrollingEnrollment in...
Trillium Announces Voting Results From the Annual and Special Meeting of Shareholders
July 02, 2019 07:00 ET
|
Trillium Therapeutics Inc.
TORONTO, July 02, 2019 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer,...
Trillium Therapeutics Reports First Quarter 2019 Financial Results
May 13, 2019 07:00 ET
|
Trillium Therapeutics Inc.
TORONTO, May 13, 2019 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today...
Trillium Announces Management and Board Changes and Provides Corporate Update
April 30, 2019 07:00 ET
|
Trillium Therapeutics Inc.
TORONTO, April 30, 2019 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for...
Trillium Therapeutics Announces Publication Highlighting Activity of TTI-621 in Sézary Syndrome Patients
April 15, 2019 07:00 ET
|
Trillium Therapeutics Inc.
TORONTO, April 15, 2019 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (Nasdaq/TSX: TRIL), a clinical-stage immuno-oncology company developing innovative therapies for the treatment of cancer, today...
Trillium Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
April 11, 2019 07:00 ET
|
Trillium Therapeutics Inc.
TORONTO, April 11, 2019 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (Nasdaq/TSX: TRIL), a clinical-stage immuno-oncology company developing innovative therapies for the treatment of cancer, today...
Trillium Therapeutics to Present at Investor Conferences in April
April 08, 2019 07:00 ET
|
Trillium Therapeutics Inc.
TORONTO, April 08, 2019 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer,...
Trillium Therapeutics Expands Immuno-Oncology Pipeline With STING Agonist Program
April 02, 2019 07:00 ET
|
Trillium Therapeutics Inc.
TORONTO, April 02, 2019 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (Nasdaq/TSX: TRIL), a clinical-stage immuno-oncology company developing innovative therapies for the treatment of cancer, today...
Trillium Therapeutics to Unveil its STING Agonist Program at the AACR Annual Meeting 2019
March 27, 2019 17:00 ET
|
Trillium Therapeutics Inc.
TORONTO, March 27, 2019 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (Nasdaq/TSX: TRIL), a clinical-stage immuno-oncology company developing innovative therapies for the treatment of cancer, today...